Raymond James & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $151M | Buy |
325,391
+14,745
| +5% | +$7.08M | 0.09% | 192 |
|
|
2024
Q2 | $146M | Sell |
310,646
-8,111
| -3% | -$3.52M | 0.1% | 181 |
|
|
2024
Q1 | $133M | Sell |
318,757
-23,660
| -7% | -$10M | 0.09% | 199 |
|
|
2023
Q4 | $139M | Buy |
342,417
+44
| +0% | +$16.3K | 0.1% | 173 |
|
|
2023
Q3 | $119M | Buy |
342,373
+10,703
| +3% | +$3.74M | 0.1% | 179 |
|
|
2023
Q2 | $117M | Sell |
331,670
-15,698
| -5% | -$5.29M | 0.1% | 190 |
|
|
2023
Q1 | $109M | Sell |
347,368
-24,958
| -7% | -$7.49M | 0.1% | 191 |
|
|
2022
Q4 | $108M | Buy |
372,326
+8,596
| +2% | +$2.62M | 0.1% | 190 |
|
|
2022
Q3 | $105M | Buy |
363,730
+3,113
| +0.9% | +$896K | 0.11% | 176 |
|
|
2022
Q2 | $102M | Sell |
360,617
-56,784
| -14% | -$15.2M | 0.1% | 186 |
|
|
2022
Q1 | $109M | Sell |
417,401
-39,682
| -9% | -$9.42M | 0.09% | 195 |
|
|
2021
Q4 | $100M | Buy |
457,083
+17,602
| +4% | +$3.42M | 0.08% | 211 |
|
|
2021
Q3 | $79.7M | Buy |
439,481
+131,559
| +43% | +$25.7M | 0.07% | 241 |
|
|
2021
Q2 | $62.1M | Sell |
307,922
-2,894
| -0.9% | -$605K | 0.06% | 290 |
|
|
2021
Q1 | $66.8M | Buy |
310,816
+26,510
| +9% | +$5.82M | 0.07% | 245 |
|
|
2020
Q4 | $67.2M | Buy |
284,306
+8,641
| +3% | +$1.98M | 0.07% | 230 |
|
|
2020
Q3 | $75M | Sell |
275,665
-1,015
| -0.4% | -$280K | 0.09% | 174 |
|
|
2020
Q2 | $80.3M | Buy |
276,680
+32,988
| +14% | +$8.94M | 0.11% | 162 |
|
|
2020
Q1 | $58M | Sell |
243,692
-105,333
| -30% | -$24.2M | 0.09% | 181 |
|
|
2019
Q4 | $76.4M | Sell |
349,025
-15,819
| -4% | -$3.2M | 0.1% | 182 |
|
|
2019
Q3 | $61.8M | Sell |
364,844
-16,191
| -4% | -$2.86M | 0.09% | 214 |
|
|
2019
Q2 | $69.9M | Sell |
381,035
-15,397
| -4% | -$2.69M | 0.1% | 184 |
|
|
2019
Q1 | $72.9M | Sell |
396,432
-5,278
| -1% | -$975K | 0.11% | 171 |
|
|
2018
Q4 | $66.6M | Sell |
401,710
-22,974
| -5% | -$3.98M | 0.12% | 164 |
|
|
2018
Q3 | $81.9M | Buy |
424,684
+12,582
| +3% | +$2.24M | 0.13% | 150 |
|
|
2018
Q2 | $70M | Sell |
412,102
-16,209
| -4% | -$2.51M | 0.12% | 162 |
|
|
2018
Q1 | $69.8M | Buy |
428,311
+20,682
| +5% | +$3.38M | 0.13% | 161 |
|
|
2017
Q4 | $61.1M | Buy |
407,629
+2,081
| +0.5% | +$308K | 0.11% | 173 |
|
|
2017
Q3 | $61.7M | Buy |
405,548
+40,394
| +11% | +$6.08M | 0.12% | 161 |
|
|
2017
Q2 | $47.1M | Buy |
365,154
+26,176
| +8% | +$3.15M | 0.1% | 194 |
|
|
2017
Q1 | $37.1M | Buy |
338,978
+29,624
| +10% | +$2.61M | 0.09% | 231 |
|
|
2016
Q4 | $22.8M | Sell |
309,354
-14,788
| -5% | -$1.2M | 0.06% | 324 |
|
|
2016
Q3 | $28.3M | Buy |
324,142
+9,285
| +3% | +$877K | 0.08% | 253 |
|
|
2016
Q2 | $27.1M | Buy |
314,857
+3,050
| +1% | +$264K | 0.08% | 250 |
|
|
2016
Q1 | $24.8M | Buy |
311,807
+11,969
| +4% | +$1.08M | 0.08% | 256 |
|
|
2015
Q4 | $37.7M | Buy |
299,838
+20,557
| +7% | +$2.48M | 0.14% | 161 |
|
|
2015
Q3 | $29.1M | Sell |
279,281
-7,538
| -3% | -$968K | 0.12% | 184 |
|
|
2015
Q2 | $35.4M | Buy |
286,819
+34,914
| +14% | +$4.4M | 0.14% | 159 |
|
|
2015
Q1 | $29.7M | Buy |
251,905
+38,981
| +18% | +$4.67M | 0.13% | 161 |
|
|
2014
Q4 | $25.3M | Buy |
212,924
+59,224
| +39% | +$6.67M | 0.12% | 172 |
|
|
2014
Q3 | $17.3M | Buy |
153,700
+11,274
| +8% | +$1.07M | 0.1% | 224 |
|
|
2014
Q2 | $13.5M | Buy |
142,426
+22,716
| +19% | +$1.59M | 0.08% | 259 |
|
|
2014
Q1 | $8.47M | Buy |
119,710
+5,566
| +5% | +$441K | 0.06% | 373 |
|
|
2013
Q4 | $8.48M | Buy |
114,144
+19,933
| +21% | +$1.39M | 0.06% | 341 |
|
|
2013
Q3 | $7.14M | Sell |
94,211
-571
| -0.6% | -$45.4K | 0.06% | 355 |
|
|
2013
Q2 | $7.59M | Buy |
+94,782
| New | +$6.98M | 0.07% | 315 |
|
Other funds holding VRTX
Raymond James & Associates's VRTX Position: Q3 2024 in Review
Raymond James & Associates increased its Vertex Pharmaceuticals (VRTX) stake by 4.7% in Q3 2024, buying an estimated $7.08M and bringing the position to 325,391 shares worth $151M. The position accounts for 0.09% of the portfolio, ranked #192.
Raymond James & Associates first reported a position in VRTX in Q2 2013 and has held it in 46 quarters since. 1,545 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.
- Raymond James & Associates held 325,391 shares of Vertex Pharmaceuticals worth $151M as of Q3 2024.
- Raymond James & Associates bought 14,745 Vertex Pharmaceuticals shares in Q3 2024, an estimated $7.08M.
- Vertex Pharmaceuticals made up 0.09% of Raymond James & Associates's portfolio in Q3 2024, its #192 holding.
- Raymond James & Associates first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 46 quarters since.
- 1,545 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.